BACKGROUND: Diabetic neuropathy is a common cause of painful diabetic neuropathy (PDN). C-X-C chemokine receptor type 4 (CXCR4) expression is increased in peripheral nerve samples from diabetes patients, suggesting a role for CXCR4 in PDN. Therefore, we evaluated the effects of Phα1β, ω-conotoxin MVIIA, and AMD3100 in a model of streptozotocin (STZ)-induced PDN in rodents and naïve model of rats with the activation of the CXCR4/stromal cell-derived factor 1 (SDF-1) signal. METHODS: Diabetic neuropathy was induced by intraperitoneal (ip) injection of STZ in Wistar rats. Naïve rats were intrathecally injected with SDF-1 to test the CXCR4/SDF-1 signal. The effects of Phα1β intrathecal (it), ω-conotoxin MVIIA intrathecal (it), and AMD3100 intraperitoneal (ip) on rat hypersensitivity, IL-6, and the intracellular calcium [Ca2+]i content of diabetic synaptosomes were studied. RESULTS: The drugs reduced the hypersensitivity in diabetic rats. SDF-1 (1.0 µg/it) administration in naïve rats induced hypersensitivity. Phα1β (100 pmol/it) or AMD3100 (2.5 µg/ip) reduced this hypersensitivity after 2 h treatments, while ω-conotoxin MVIIA did not have an effect. IL-6 and [Ca2+]i content increased in the spinal cord synaptosomes in diabetic rats. The drug treatments reduced IL-6 and the calcium influx in diabetic synaptosomes. CONCLUSIONS: Phα1β, ω-conotoxin MVIIA, and AMD3100, after 2 h of treatment of STZ-induced PDN, reduced hypersensitivity in diabetic rats. In naïve rats with CXCR4/SDF-1 activation, the induced hypersensitivity decreased after 2 h treatments with Phα1β or AMD-3100, while ω-conotoxin MVIIA did not affect. The inhibitory effects of Phα1β on PDN may involve voltage-dependent calcium channels.
BACKGROUND:Diabetic neuropathy is a common cause of painful diabetic neuropathy (PDN). C-X-C chemokine receptor type 4 (CXCR4) expression is increased in peripheral nerve samples from diabetespatients, suggesting a role for CXCR4 in PDN. Therefore, we evaluated the effects of Phα1β, ω-conotoxin MVIIA, and AMD3100 in a model of streptozotocin (STZ)-induced PDN in rodents and naïve model of rats with the activation of the CXCR4/stromal cell-derived factor 1 (SDF-1) signal. METHODS:Diabetic neuropathy was induced by intraperitoneal (ip) injection of STZ in Wistar rats. Naïve rats were intrathecally injected with SDF-1 to test the CXCR4/SDF-1 signal. The effects of Phα1β intrathecal (it), ω-conotoxin MVIIA intrathecal (it), and AMD3100 intraperitoneal (ip) on rathypersensitivity, IL-6, and the intracellular calcium [Ca2+]i content of diabetic synaptosomes were studied. RESULTS: The drugs reduced the hypersensitivity in diabeticrats. SDF-1 (1.0 µg/it) administration in naïve rats induced hypersensitivity. Phα1β (100 pmol/it) or AMD3100 (2.5 µg/ip) reduced this hypersensitivity after 2 h treatments, while ω-conotoxin MVIIA did not have an effect. IL-6 and [Ca2+]i content increased in the spinal cord synaptosomes in diabeticrats. The drug treatments reduced IL-6 and the calcium influx in diabetic synaptosomes. CONCLUSIONS: Phα1β, ω-conotoxin MVIIA, and AMD3100, after 2 h of treatment of STZ-induced PDN, reduced hypersensitivity in diabeticrats. In naïve rats with CXCR4/SDF-1 activation, the induced hypersensitivity decreased after 2 h treatments with Phα1β or AMD-3100, while ω-conotoxin MVIIA did not affect. The inhibitory effects of Phα1β on PDN may involve voltage-dependent calcium channels.
Authors: Alessandra H Souza; Juliano Ferreira; Marta do Nascimento Cordeiro; Luciene Bruno Vieira; Celio J De Castro; Gabriela Trevisan; Helton Reis; Ivana Assis Souza; Michael Richardson; Marco A M Prado; Vânia F Prado; Marcus Vinicius Gomez Journal: Pain Date: 2008-09-06 Impact factor: 6.961
Authors: Troels S Jensen; Ralf Baron; Maija Haanpää; Eija Kalso; John D Loeser; Andrew S C Rice; Rolf-Detlef Treede Journal: Pain Date: 2011-07-18 Impact factor: 6.961
Authors: Luciene B Vieira; Christopher Kushmerick; Michael E Hildebrand; Esperanza Garcia; Antony Stea; Marta N Cordeiro; Michael Richardson; Marcus Vinicius Gomez; Terrance P Snutch Journal: J Pharmacol Exp Ther Date: 2005-06-02 Impact factor: 4.030
Authors: Peter S Staats; Thomas Yearwood; Steven G Charapata; Robert W Presley; Mark S Wallace; Michael Byas-Smith; Robert Fisher; David A Bryce; Eugene A Mangieri; Robert R Luther; Martha Mayo; Dawn McGuire; David Ellis Journal: JAMA Date: 2004-01-07 Impact factor: 56.272
Authors: Gowhar Ali; Fazal Subhan; Muzaffar Abbas; Jehan Zeb; Muhammad Shahid; Robert D E Sewell Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2015-07-03 Impact factor: 3.000
Authors: Carolina Nunes da Silva; Kenia Pedrosa Nunes; Lays Fernanda Nunes Dourado; Thayllon Oliveira Vieira; Xavier Maia Mariano; Armando da Silva Cunha Junior; Maria Elena de Lima Journal: Front Mol Biosci Date: 2022-04-11